摘要
慢性乙型肝炎以及乙肝肝硬化人群,推荐长期乃至于终生服用抗乙型肝炎病毒(hepatitis B virus,HBV)的药物核苷(酸)类药物,因此需要特别关注短期以及长期用药的安全性问题。富马酸替诺福韦二吡呋酯(tenofovir disoproxil fumarate,TDF)是治疗慢性乙型肝炎的核苷(酸)类药物的一线用药,其肾脏安全性一直备受关注。慢性乙型肝炎以及肝硬化人群本身就是肾脏损伤的易感人群。已发表的大规模注册的临床研究中,参与研究的均为符合入组标准与排除标准的经过筛选的人群,而真实世界中却无法按照各种标准选择患者。因此本文将对TDF在慢性乙型肝炎以及乙肝肝硬化人群的肾脏安全性进行综述,旨在指导临床医生在此类人群中更安全地选择抗HBV药物。
Patients with chronic hepatitis B and hepatitis B-related cirrhosis should take drugs for antihepatitis B virus(HBV)life-long,which would take into account the short-term and long-term safety.Tenofovir disoproxil fumarate(TDF)is recommended as first-line treatment for hepatitis B virus infection.It is very important to emphasize the nephrotoxic effect of TDF in short-term and long-term.Patients with chronic hepatitis B and hepatitis B-related cirrhosis are at a high risk of developing kidney injury.A large scale of registered clinical study must recruit patients according to inclusion criteria and exclusion criteria,means a selected population,which is quite different from the population of real-world study.In this review,we will focus on the renal safety of TDF in patients with chronic hepatitis B and hepatitis B-related cirrhosis,which would guide physicians to prescript the optimal drugs for anti-HBV.
作者
闻颖
唐诗
WEN Ying;TANG Shi(Department of Infectious Diseases,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)
出处
《实用医学杂志》
CAS
北大核心
2020年第19期2740-2743,共4页
The Journal of Practical Medicine
基金
北京医卫健康公益基金项目(编号:YWJKJJHKYJJ-Q2101)。
